Search Results
Search for other papers by Yuegui Wang in
Google Scholar
PubMed
Search for other papers by Liwei Hong in
Google Scholar
PubMed
School of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, China
Search for other papers by Caiyun Yang in
Google Scholar
PubMed
Quanzhou Medical College, Quanzhou, Fujian, China
Search for other papers by Guorong Lv in
Google Scholar
PubMed
Search for other papers by Kangjian Wang in
Google Scholar
PubMed
Search for other papers by Xuepeng Huang in
Google Scholar
PubMed
Search for other papers by Haolin Shen in
Google Scholar
PubMed
orbitopathy ( 5 ). Therapies for GD include antithyroid drugs (ATDs), thyroidectomy, or radioactive iodine (RAI) therapy. ATD has only a 50% success rate for most patients after 1 year of treatment, and it may cause side effects such as agranulocytosis
Search for other papers by Lian Duan in
Google Scholar
PubMed
Search for other papers by Han-Yu Zhang in
Google Scholar
PubMed
Search for other papers by Min Lv in
Google Scholar
PubMed
Search for other papers by Han Zhang in
Google Scholar
PubMed
Search for other papers by Yao Chen in
Google Scholar
PubMed
Search for other papers by Ting Wang in
Google Scholar
PubMed
Search for other papers by Yan Li in
Google Scholar
PubMed
Search for other papers by Yan Wu in
Google Scholar
PubMed
Search for other papers by Junfeng Li in
Google Scholar
PubMed
Search for other papers by Kefeng Li in
Google Scholar
PubMed
validation set. RAI, radioiodine therapy; ROC, receiver operator characteristic curve; HT, hypothyroidism; NC, the normal control group; AST, aspartate aminotransferase; TRAb, thyrotropin-receptor antibodies; 24-h RAIU, radioactive iodine uptake at 24 h; TMA
Search for other papers by Yanling Cai in
Google Scholar
PubMed
Search for other papers by Yan Yang in
Google Scholar
PubMed
Search for other papers by Xiao Pang in
Google Scholar
PubMed
Search for other papers by Suping Li in
Google Scholar
PubMed
. TC among male patients tends to be more aggressive at the time of diagnosis and may be associated with a poor prognosis ( 1 , 2 ). This implies a higher TC risk stratification in men. Radioactive iodine therapy (RAI or 131 I therapy) is the main
Search for other papers by Sara Ahmadi in
Google Scholar
PubMed
Search for other papers by Alexandra Coleman in
Google Scholar
PubMed
Endocrinology Service, Instituto Nacional de Câncer, Rio de Janeiro, Brazil
Search for other papers by Nathalie Silva de Morais in
Google Scholar
PubMed
Search for other papers by Iñigo Landa in
Google Scholar
PubMed
Search for other papers by Theodora Pappa in
Google Scholar
PubMed
Search for other papers by Alex Kang in
Google Scholar
PubMed
Search for other papers by Matthew I Kim in
Google Scholar
PubMed
Search for other papers by Ellen Marqusee in
Google Scholar
PubMed
Search for other papers by Erik K Alexander in
Google Scholar
PubMed
to treatment in all cases. Planar scintigraphy and SPECT-CT were performed 5–7 days after radioactive iodine treatment. All patients receiving I-131 therapy had undergone near-total thyroidectomy as the primary treatment of the disease. Imaging was
Search for other papers by Qian Yang in
Google Scholar
PubMed
Search for other papers by Wencai Ke in
Google Scholar
PubMed
Search for other papers by Fanfan Pan in
Google Scholar
PubMed
Search for other papers by Xinmei Huang in
Google Scholar
PubMed
Search for other papers by Jun Liu in
Google Scholar
PubMed
Search for other papers by Bingbing Zha in
Google Scholar
PubMed
Introduction Graves' disease (GD), also known as an organ-specific autoimmune disorder, is characterized by high radioactive iodine uptake (RAIU) and hyperthyroidism ( 1 ). Excessive production of thyroid hormones results in a substantially
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Kim Magaly Pabst in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
Search for other papers by Robert Seifert in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Nader Hirmas in
Google Scholar
PubMed
Search for other papers by Martina Broecker-Preuss in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Manuel Weber in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Wolfgang Peter Fendler in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Timo Bartel in
Google Scholar
PubMed
Institute of Pathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
Search for other papers by Sarah Theurer in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Ken Herrmann in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Rainer Görges in
Google Scholar
PubMed
Brokhin M Omry G Fagin JA Shaha A . Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates
Search for other papers by Hyunjae Lee in
Google Scholar
PubMed
Search for other papers by Tae-Shin Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Search for other papers by Ja-Yoon Gu in
Google Scholar
PubMed
Search for other papers by Mi Ran Yu in
Google Scholar
PubMed
Search for other papers by Seung-Eun Lee in
Google Scholar
PubMed
Search for other papers by Eun Sook Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Search for other papers by Hyun Kyung Kim in
Google Scholar
PubMed
greatest prevalence in both groups, followed by stage II. The proportion of patients who received postoperative radioactive iodine therapy did not significantly differ between two groups. Table 1 Clinicopathologic characteristics of 122 patients with
Search for other papers by Yukari Maki in
Google Scholar
PubMed
Search for other papers by Kiyomi Horiuchi in
Google Scholar
PubMed
Search for other papers by Takahiro Okamoto in
Google Scholar
PubMed
underwent less than total thyroidectomy, 206 (70.5%) were on levothyroxine replacement therapy. Approximately 20% of patients received radioactive iodine treatment. Over half (53.1%) of the patients maintained their TSH level within the reference range. The
Search for other papers by Sara Ahmadi in
Google Scholar
PubMed
Search for other papers by Iñigo Landa in
Google Scholar
PubMed
. Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy . Clinical Cancer Research 2023 29 1620 – 1630 . ( https://doi.org/10.1158/1078-0432.CCR-22-2882 ) 72 Yoo SK Song YS
Search for other papers by Ayse Nurcan Cebeci in
Google Scholar
PubMed
Search for other papers by Vera Schempp in
Google Scholar
PubMed
Search for other papers by Katharina Förtsch in
Google Scholar
PubMed
Search for other papers by Bettina Gohlke in
Google Scholar
PubMed
Search for other papers by Michaela Marx in
Google Scholar
PubMed
Search for other papers by Helmuth-Guenther Dörr in
Google Scholar
PubMed
Search for other papers by Joachim Woelfle in
Google Scholar
PubMed
, and definitive treatment options should be discussed in case of failure or intolerance of medical treatment ( 26 ). The current options for definitive treatment include radioactive iodine therapy or surgical thyroidectomy. It has been suggested that